Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Clinical study director
G1 Therapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
34 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hopitaux Universitaires de Strasbourg - Service Oncologie Et Hématologie
Strasbourg, Bas-Rhin, France
- Institut Bergonié - Oncologie Médicale Et Pédiatrique
Bordeaux, Gironde, France
- Centre Léon Bérard - Département D'Oncologie Médicale
Lyon, France
- Hôpital Européen Georges Pompidou - Service D'Oncologie Médicale
Paris, France
- Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France
- High Technology Hospital Medcenter Ltd
Batumi, Adjara, Georgia
- Ltd "multiprofile Clinic Consilium Medulla"
Tbilisi, Georgia
- National Center of Urology Named After Laur Managadze
Tbilisi, Georgia
- Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz - Rendeloint
Szolnok, Jász-Nagykun-Szolnok, Hungary
- Országos Onkológiai Intézet
Budapest, Hungary
- Uzsoki Utcai Kórház
Budapest, Hungary
- Institut Català D'Oncologia-Hospital Universitari Germans Trias I Pujol
Badalona, Barcelona, Spain
- Althaia, Xarxa Assistencial Universitiria de Manresa
Manresa, Barcelona, Spain
- Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Madrid, Spain
- Hospital Clinic de Barcelona - Servicio de Oncología Médica
Barcelona, Spain
- Hospital Universitario Vall D´hebron
Barcelona, Spain
- Hospital de la Santa Creu I Sant Pau
Barcelona, Spain
- H.U. V. de Las Nieves
Granada, Spain
- Hospital Universitario Lucus Augusti
Lugo, Spain
- Fundación Instituto Valenciano de Oncología
Valencia, Spain
- Hospital Politecnic Universitari la Fe
Valencia, Spain
- Valkyrie Clinical Trial
Los Angeles, California, United States
- the Oncology Institute of Hope and Innovation
Whittier, California, United States
- Rocky Mountain Cancer Centers
Littleton, Colorado, United States
- Florida Cancer Specialists - South
Fort Myers, Florida, United States
- Woodlands Medical Specialists
Pensacola, Florida, United States
- Florida Cancer Specialists - North
St. Petersburg, Florida, United States
- Beacon Cancer Center Pllc
Coeur d'Alene, Idaho, United States
- the Harry and Jeanette Weinberg Cancer Institute
Baltimore, Maryland, United States
- New York Oncology Hematology, P.C.
Albany, New York, United States
- Montefiore Medical Center
The Bronx, New York, United States
- University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
- Northwest Cancer Specialists, P.C.
Tigard, Oregon, United States
- Tennessee Oncology, Pllc
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Jun 2021
- Primary completion
- 7 Apr 2023
- Completion
- 1 Mar 2024
- Last update posted
- 8 Sept 2025
- Registered enrollment
- 92
- Registry id
- NCT04887831
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.